Press Releases

09.09.2019 | Launch of the FLEXcyte 96 – pushing the boundaries of cardiac safety screening

MUNICH, GERMANY, 09. September 2019: Nanion is pleased to announce the launch of the FLEXcyte 96 technology for cardiac contraction force measurements. Improving patient safety and reducing animal tests while saving time and money by replacing unnecessary in vivo experiments is the aim of this novel assay technology. The FLEXcyte 96 has been developed in cooperation with innoVitro GmbH.

Continue Reading

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.